Skip to main content

Making the compound Amanitin available for cancer therapies

Our mission is to research and develop drugs for cancer patients to provide them
with a targeted, tailor-made and highly effective treatment option

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.

News

PR: Heidelberg Pharma Announces Changes to the Executive Management Board
29 November 2023
Open
AH: Heidelberg Pharma Announces Changes to the Executive Management Board
29 November 2023
Open
PR: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
15 November 2023
Open
PR: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
02 November 2023
Open

Meet us

Deutsches Eigenkapitalforum
27. - 29. November
ASH Annual Meeting
9. - 12. Dezember

Partner Information

TitleDate
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
31 July 2023
Read more
Telix: First Patient Dosed in STARSTRUCK Study
19 July 2023
Read more
Telix: First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
19 June 2023
Read more